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Abstract
The stability and subcellular localization of beta-catenin, a protein that plays a major role in cell adhesion and proliferation,
is tightly regulated by multiple signaling pathways. While aberrant activation of beta-catenin signaling has been implicated
in cancers, the biochemical identity of transcriptionally active beta-catenin (ABC), commonly known as unphosphorylated
serine 37 (S37) and threonine 41 (T41) b-catenin, remains elusive. Our current study demonstrates that ABC transcriptional
activity is influenced by phosphorylation of T120 by Protein Kinase D1 (PKD1). Whereas the nuclear b-catenin from PKD1-
low prostate cancer cell line C4-2 is unphosphorylated S37/T41/T120 with high transcription activity, the nuclear b-catenin
from PKD1-overexpressing C4-2 cells is highly phosphorylated at T120, S37 and T41 with low transcription activity, implying
that accumulation of nuclear b-catenin alone cannot be simply used as a read-out for Wnt activation. In human normal
prostate tissue, the phosphorylated T120 b-catenin is mainly localized to the trans-Golgi network (TGN, 22/30, 73%), and this
pattern is significantly altered in prostate cancer (14/197, 7.1%), which is consistent with known down regulation of PKD1 in
prostate cancer. These in vitro and in vivo data unveil a previously unrecognized post-translational modification of ABC
through T120 phosphorylation by PKD1, which alters subcellular localization and transcriptional activity of b-catenin. Our
results support the view that b-catenin signaling activity is regulated by spatial compartmentation and post-translational
modifications and protein level of b-catenin alone is insufficient to count signaling activity.
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Introduction
Beta-catenin is a dual functional molecule which plays a
structural role in cell-cell adhesion and a mediator for cellular
signaling pathways [1]. b-catenin bridges the epithelial cell surface
to cytoskeletal networks by binding to membranous molecule E-
cadherin and a-catenin, which links to F-actin and cytoskeleton
[1]. The catenin/cadherin protein complex is necessary to
establish and maintain cell-cell adhesion [2]. On the other hand,
b-catenin is also a co-activator in transcription activities through
Wingless/Wnt and androgen receptor signaling pathways in
prostate epithelial cells by forming a complex with either T-cell
factor (TCF) or androgen receptor [1,3,4]. b-catenin has 12
Armadillo repeats in the middle of its sequence which form a
superhelix of helices that create a positively charged groove to
interact with many of its negatively charged ligands [5,6]. This
versatility of using a single binding region must be highly regulated
to determine when and where b-catenin binds to different ligands.
Evidence is accumulating that the N-terminal of b-catenin plays a
key role in control b-catenin protein stability, subcellular
localization and transcription activity [7].
Early studies show that b-catenin has two major pools: plasma
membrane pool bound to E-cadherin which is relatively stable and
cytoplasmic pool in a complex consisting of glycogen synthase
kinase-3 (GSK-3), adenomatous polyposis coli (APC) and Axin
that is dynamically balanced between degradation and accumu-
lation. The degradation is ubquitin-mediated by sequential
phosphorylation on S33, S37, T41 (by GSK3) and S45 (by CKI)
in the absence of Wnt signaling. Recent work suggests that the N-
terminal phosphorylation of b-catenin has functions beyond
controlling protein degradation. b-catenin with phosphorylated
S45 tends to accumulate in nucleus and spatially separates from
isoform with S33/S37/T41 phosphorylation [8]. The S33/S37/
T41/S45 phosphorylated b-catenin localizes at several subcellular
sites, including cell-cell contacts where the phosphorylated b-
catenin associates with E-cadherin at the adherens junction and
with APC at cell protrusions [9,10]. These data suggest that N-
terminally phosphorylated b-catenin may serve distinct functions
in nucleus and cell migration. A key consequence of the Wnt
signaling is to generate and accumulate nuclear transcriptionally
active b-catenin (ABC), which has been known as unpho-
sphorylated at S37/T41 [11,12]. However, this b-catenin isoform,
recognized by a monoclonal antibody 8E7 [11,12], is more readily
detected at plasma membrane in complex with E-cadherin
[13,14]. In E-cadherin negative cells, this isoform is primarily
monomeric in cytoplasm [14]. Upon Wnt stimulation, this isoform
first moves to plasma membrane to form a complex with APC and
LRP5 and then translocates to nucleus [13].
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Protein Kinase D1 (PKD1), a serine/threonine kinase, has been
implicated in numerous cellular functions, including cell survival,
migration, differentiation, proliferation and cell-cell adhesion
[15,16]. PKD1 has been reported to be downregulated in
advanced prostate, breast and gastric cancers and shown to play
a role in tumorigenesis and metastasis [17,18,19]. Embryonic
deletion of PKD1 in mice is lethal [20], suggesting PKD1 plays a
crucial role in development, which cannot be replaced by other
PKD family members, PKD2 and PKD3. We previously showed
that PKD1 phosphorylates b-catenin at T112 and T120 [21]. The
T120 residue is critical for binding to a-catenin since mutation of
T120 to alanine abolished a-catenin binding [22]. Crystal
structure analysis of b-catenin showed that the T120 residue
locates at the beginning of a-catenin binding domain [5,6].
Overexpression of PKD1 in prostate cancer C4-2 cell line, which
has low endogenous PKD1 expression [23], suppresses epithelial
to mesenchymal transition and tumor incidence in mice xenograft
model [24]. PKD1 suppresses transcription factor Snail, a known
E-cadherin repressor by inhibitory phosphorylation, induces
expression of E-cadherin and up-regulates b-catenin [24].
However, high level of total b-catenin alone in C4-2/PKD1 cells
is not sufficient to induce Wnt signaling [24]. Using a recently
developed and characterized phosphor-threonine specific antibody
that recognizes the phosphorylated T120 of b-catenin (pT120), we
found that the nuclear b-catenin in C4-2/PKD1 cells is more
reactive to the pT120 antibody and not recognized by the 8E7
antibody. In contrast, the nuclear b-catenin in C4-2 cells is not
reactive to the pT120 antibody, but recognized by the 8E7
antibody. These results suggest that PKD1 activity influences the
post-translational modifications and transcription activity of b-
catenin via T120 phosphorylation. The pT120 antibody also
reveals b-catenin accumulation in transGolgi network (TGN) in
normal prostate tissue, but diminished in prostate cancer.
Results
PKD1 inhibits b-catenin transcription activity
We showed previously that overexpression of PKD1 suppressed
cell proliferation and motility [21] and induced b-catenin
membrane trafficking [28]. To study the influence of PKD1 on
b-catenin function, we first measured b-catenin transcription
activity using Topflash assay in the presence of PKD1. Wild type
PKD1 was able to suppress the b-catenin/TCF transcription
activity. In contrast, a kinase-dead mutant PKD1 (S744A/S748A)
failed to inhibit the b-catenin/TCF transcription activity (Fig. 1A).
Next, we compared expressions of endogenous Wnt target genes in
prostate cancer C4-2 cell line and C4-2 cells that overexpress
PKD1 (C4-2/PKD1). The high metastatic C4-2 cell line was
derived from low metastatic LNCaP cell line by recovering tumor
cells from metastatic sites in mice xenograft [29]. The C4-2 cell
has lower endogenous PKD1 protein expression compared to
parental LNCaP cells [17]. Semi-quantitative RT-PCR shows that
Wnt/b-catenin target genes were expressed more in C4-2 cells
than those in C4-2/PKD1 cells (Fig. 1B). These results suggest that
Wnt/b-catenin is more active in C4-2 cells than in C4-2/PKD1
cells.
Since PKD1 directly phosphorylates b-catenin at threonine-112
and 120 residues, we examined the subcellular locations of b-
catenin in the presence and absence of PKD1 activity. The
endogenous b-catenin localizes to plasma membrane and a
Figure 1. PKD1 represses Wnt/b-catenin transcription activity. (A) PKD1 inhibits b-catenin/TCF transcription activity. Topflash assay was
performed in LNCaP cells. Data were normalized by Renilla luciferase activity based on average of triple samples. Error bars represent standard
deviation. Significant difference between the control and tested groups were determined by Student’s t-test. (B) Overexpression of PKD1 in C4-2 cells
results in inhibition of Wnt target genes. Representative results of semi-quantitative RT-PCR for Wnt/b-catenin target genes from two independent
assays (see Materials and Methods). (C) b-catenin in C4-2/PKD1 cells is co-localized with TGN marker p230 (white arrows). When the cells were treated
with PKD1 small molecule inhibitor CID 755763 (50 nM) for 3days, the pattern is decreased (D). Anti b-catenin antibody H102 was used to stain
endogenous b-catenin (red). TGN marker p230 and nuclei were labeled green. Images represent typical results from two tests.
doi:10.1371/journal.pone.0033830.g001
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portion of cytoplasm b-catenin accumulates in transGolgi Network
(TGN), where it co-localizes with TGN marker P230 (white
arrows, Fig. 1C). Pre-incubation with a PKD1 small molecule
inhibitor CID755673 [30], the accumulation of b-catenin in TGN
becomes diminished (Fig. 1D).
Development and characterization of pT120 antibody
Among the two PKD1 phosphorylation sites T112 and T120,
T112 is also a site for casein kinase II (CKII) phosphorylation [31],
PKD1 is the only known kinase to phosphorylate T120.
Therefore, we chose the pT120 for developing phosphothreonine
specific antibody (see Materials and Methods).
In order to confirm specificity of pT120 antibody, we first
transfected HA-tagged wild type, T120I and T102I/T112R/
T120I mutants of b-catenin into mouse 3T3 cell, a PKD1 positive
cell line [32]. Cell lysates were used for Western blot. The pT120
antibody recognizes wild type b-catenin presumably phosphory-
lated, but not the mutants that lack T120 phosphorylation
(Fig. 2A), suggesting the pT120 antibody specifically recognizes
T120 phosphorylation.
Next, we compared the pT120 b-catenin in C4-2 and C4-2/
PKD1 cells. Cell lysates from C4-2 cells and C4-2/PKD1 were
blotted with either a conventional b-catenin H102 antibody (for
detection total b-catenin) or pT120 antibody (Fig. 2B). The H102
antibody detects a major b-catenin band around 90 kDa in both
C4-2 and C4-2/PKD1 cells and a minor band below 90 kDa in
C4-2/PKD1 cell lysate only (arrowhead in lane 2). The pT120
antibody strongly reacts to the lower band in C4-2/PKD1 cell
(arrowhead, lane 4) and weakly to the band at 90 kDa in C4-2 cells
(arrow, lane 3). The results are consistent with our previous
observation that the PKD1 phosphorylated b-catenin abnormally
appeared at lower molecular weight, although phosphorylated
proteins usually appear at higher molecular weights in most cases
[21]. To further address the specificity of this pT120 antibody, we
performed peptide competition assay. The antigenic phosphopep-
tide and non-phospho (normal) peptide were pre-mixed with the
pT120 antibody individually and used to blot C4-2/PKD1 cell
lysate. The phosphopeptide can compete with pT120 antibody
binding (lane 6), but not the normal peptide (lane 7). Finally,
knockdown PKD1 protein levels in LNCaP cells by shRNA
resulted in lower pT120 antibody signal (Fig. 2C), suggesting that
the T120 residue is a phosphorylation site for PKD1 in vitro. The
data suggests that that pT120 antibody specifically recognizes the
T120 phosphorylation of b-catenin.
Overexpression of PKD1 blocks nuclear accumulation of
active b-catenin
To study the influence of PKD1 activity on b-catenin, we
compared b-catenin subcellular distribution in C4-2 and C4-2/
PKD1 cells. Subcellular fractions enriched with soluble cytosolic,
nuclear or total membrane fractions (including organelle and
plasma membranes) were prepared and blotted with pT120, 8E7
(for ABC), pS33/S37/T41, and H102 antibodies (Fig. 3A). In C4-
2 cells, the pT120 b-catenin is predominately localized to total
membrane fraction, with minor amounts in soluble cytosol and
nucleus (lanes 1–3). In contrast, the pT120 b-catenin is readily
detected in every subcellular fraction of C4-2/PKD1 cells (lanes
4–6). The active b-catenin detected by 8E7 antibody generally
demonstrates an inverse relationship to pT120 b-catenin, i.e. high
levels of ABC in C4-2, especially in nuclei (lane 2). The nuclear
Figure 2. Characterization of pT120 antibody. (A) NIH 3T3 lysates that were transfected with either HA-tagged wild type, or T102I/T112R/T120I
triple mutant, or T120I mutant b-catenin and blotted by pT120 antibody. (B) Cell lysates from C4-2 (lanes 1 and 3) and C4-2/PKD1 (lanes 2 and 4 to 7)
cells were blotted with either b-catenin conventional antibody H102 (lanes 1 and 2) or pT120 antibody (lanes 3–7). Competition assay was performed
in C4-2/PKD1 cell lysate in the presence of 20 nM of antigenic phospho-peptide (lane 6) or the nonphospho-peptide (lane 7). (C) Inhibition of PKD1
activity decreases T120 phosphorylation. LNCaP cells were transiently transfected with two shRNA targeting PKD1 or a control shRNA vector. Cell
lysates were blotted with antibodies indicated. The relative protein levels quantified by densitometry are expressed as fraction of the control group
on the average of two assays.
doi:10.1371/journal.pone.0033830.g002
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ABC is not detectable in the C4-2/PKD1 cells, although relative
amount of nuclear b-catenin is comparable to C4-2 cells (20% vs.
26% in C4-2 and C4-2/PKD1 cells). Furthermore, phosphorylat-
ed S33/S37/T41 primarily present in C4-2/PKD1 correlates
positively with pT120 distribution. Since the expression of Wnt
target genes in C4-2/PKD1 cells is less than those in C4-2 cells
(Fig. 1B), the nuclear b-catenin in C4-2/PKD1 cells, which
consists of phosphorylated T120 b-catenin, is less transcriptionally
active, suggesting that b-catenin protein level alone is insufficient
to count signaling activity. Large differences in total b-catenin in
cytoplasm and membrane fractions are also observed (Fig. 3A).
Since the C4-2 is an E-cadherin negative cell and C4-2/PKD1 is
an E-cadherin positive cell, it is reasoned that the b-catenin in C4-
2/PKD1 cell is more membrane bound due to binding to E-
cadherin and less likely to be found as soluble cytoplasm protein
(compare Fig. 1C and Supplementary Fig. S1a). In addition,
immunofluorescence image demonstrate that the pT120 b-catenin
in C4-2/PKD1 distributes in cytosol, nucleus and plasma
membrane and co-localizes with TGN marker p230 in cytosol
(Fig. 3C), which is consistent with H102 staining pattern (Fig. 1C).
Overexpression of PKD1 prevents Wnt-induced b-catenin
accumulation
Although C4-2 cells do not express E-cadherin, C4-2/PKD1 is
E-cadherin positive (Fig. 3A) due to inhibition of transcription
factor Snail by PKD1 ([24]). Upon Wnt3a treatment, both total
and active b-catenin increasingly accumulates in C4-2 cells after 6
and 24-hour stimulation (lanes 2 and 3, Fig. 3B). In contrast, total
and pT120 b-catenin in C4-2/PKD1 cells remains unchanged
before and after Wnt stimulation (lanes 4–6), active b-catenin
remains nearly unchanged after 6 hours treatment, prolonged
treatment (24 hours) actually decreases the amount of ABC (lane
6). Hendriksen et al. reported similar findings in mammary
epithelial cell cultures and suggested that the E-cadherin/b-
catenin membranous complex resists Wnt stimulation [13].
Interestingly, the known patterns of pT120 in un-stimulated C4-
2 and C4-2/PKD1 cells, i.e., a high molecular weight band in C4-
2 and a low molecular weight band in C4-2 PKD1 (lanes 3 and 4,
Fig. 2B) remain relatively unchanged throughout Wnt treatment.
However, a new band recognized by pT120 antibody appears and
accumulates in C4-2 cells after Wnt treatment up to 24 hours
(lanes 2 and 3).
The pT120 b-catenin accumulates at TGN of prostate
epithelial cells
We previously observed that PKD1 activity is associated with b-
catenin membrane trafficking and the two proteins co-localize
with multiple TGN markers [28], suggesting that pT120 b-catenin
may involve in b-catenin membrane trafficking. Immunofluores-
cence staining with pT120 antibody in various prostate epithelial
cells reveals that pT120 subcellular localization has different
patterns from H102 antibody. In C4-2 cells, which are E-cadherin
negative, total b-catenin level is low and cytosol (Supplementary
Figure S1a), pT120 b-catenin mainly localizes to paranuclear area.
In E-cadherin positive cells, including C4-2/PKD1, LNCaP,
RWPE1 and BPH-1 cells, the H102 antibody staining reveals b-
catenin at plasma membrane (Fig. 1C and Supplementary Figure
S1b–d). In addition, the pT120 antibody shows different
localization patterns: , In C4-2/PKD1 cells, the pT120 b-catenin
distributes to cytosol, nucleus and plasma membrane and the
Figure 3. pT120 b-catenin blocks generation of nuclear ABC and accumulates in trans Golgi network. (A) C4-2 and C4-2/PKD1 cells were
fractionated into fractions enriched for cytoplasmic, nuclear or membrane proteins and analyzed by Western blot with antibodies as noted. E-
cadherin, lamin A/C and b-actin were used as plasma membrane, nuclear and cytosol markers, respectively. The * indicates a leftover band from
previous blotting. The densitometric data of each b-catenin isoform in a cell was the average of three assays and was expressed as percentage. (B)
Overexpression of PKD1 prevents Wnt-induced b-catenin accumulation. C4-2 and C4-2/PKD1 cells were cultured with recombinant Wnt3a for
indicated times. The relative amount of b-catenin at each time point was expressed as a ratio to the amount of b-catenin at starting time 0 (data was
from a single assay). (C) Immunofluorescence staining of C4-2/PKD1 cells with pT120 and TGN p230 antibodies The TGN and pT120 colocalization are
indicated by white arrows.
doi:10.1371/journal.pone.0033830.g003
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cytosol pT120 b-catenin co-localizes with TGN (Fig. 3C). In
LNCaP and RWPE1 cells, the pT120 b-catenin distributes
predominately as diffused cytosol protein (Supplementary Fig.
S1b and S1c). However, in a benign hyperplastic prostate
epithelial BPH-1 cell line, the pT120 b-catenin shows predominate
staining on plasma membrane and nucleus (Supplementary Figure
S1d). The results suggest that the variation of subcellular
localization of pT120 may be sensitive to cellular signaling
changes in prostate cancer progression.
T120 phosphorylated b-catenin accumulates in TGN in
prostate tissue
To study the pT120 b-catenin in situ, we co-stained formalde-
hyde-fixed, paraffin embedded benign human prostate tissue using
the pT120 or H102 antibody with TGN marker p230. b-catenin
visualized by conventional H102 antibody typically localizes on
plasma membrane as well as TGN (Fig. 4A). In contrast, vast
majority of b-catenin visualized by the pT120 antibody co-
localizes with p230 on TGN (Fig. 4B). Weak staining of plasma
membrane is also detected.
To confirm the specificity of pT120 antibody using in
immunohistochemetry (IHC), we performed peptide competition
assay on pT120 antibody in IHC. The pT120 antibody staining
displays a more diffuse pattern with heavy particles in cytoplasm
presumably the TGN (left panel, Fig. 4C). In the presence of
antigenic phosphopeptide, most staining disappeared except few
spots in TGN (middle panel, Fig. 4C), the most likely explanation
for the observation is that the TGN local concentration of pT120
b-catenin is too high for the phosphopeptide to totally compete. In
contrast, the non-phosphopeptide cannot compete with pT120
antibody staining in cytoplasm but not in TGN (right panel,
Fig. 4C).
The T120 phosphorylated b-catenin in TGN dramatically
decreased in prostate cancer specimens
In order to explore utility of T120 b-catenin antibody in clinical
specimens immunohistochemical (IHC) studies were carried out.
IHC was performed on serial sections of paraffinized human
prostate normal and cancer samples arranged on tissue arrays to
compare pT120 b-catenin to total b-catenin distribution (Fig. 5A1,
A2, B1 and B2). In normal samples, the pT120 antibody typically
showed diffuse cytoplasm staining with heavy TGN particles
(arrows, Fig. 5B3). Twenty-two of 30 (73.3%) benign prostate
tissues demonstrated pT120 b-catenin in TGN (Table 1) as judged
by over 30 TGN particles. In contrast, 183/197 (92.9%) cancer
specimens showed no pT120 b-catenin accumulation in TGN
compared to benign prostate tissues (Fig. 5C, p,0.001). Cancer
specimens with Gleason grade $7 showed even lower percentage
of positive TGN staining (6.3%) versus 14.8% positive staining
from specimens with Gleason 3–6. Table 1 summarizes the finding
of pT120 antibody staining in human prostate cancer tissues. In
addition, two samples contain both tumor tissues and adjacent
normal glands. The pT120 antibody staining shows that pT120 b-
catenin only accumulates in tumor adjacent normal glands
(arrows, Supplementary Figure S2), not in tumor tissue.
Other abnormal pT120 antibody staining patterns also found in
prostate cancer samples, including strong plasma membrane
(Fig. 5B4) and nuclear staining (Fig. 5B5), which may resemble
patterns found in BPH1 cells (Supplementary Figure S1c). Table 2
summarizes the finding of these abnormalities.
Discussion
PKD1 suppresses cancer cell epithelial to mesenchymal
transition by inhibitory phosphorylation of transcription factor
Snail, a known E-cadherin repressor. Overexpression of PKD1 in
Figure 4. pT120 b-catenin localizes in TGN in normal prostate tissue. Formalin fixed and paraffinized normal human prostate tissues were
stained with either b-catenin H102 (A) or pT120 (B) antibodies with TGN marker p230 antibody. Nucleus was stained in blue. Inserts are higher
magnification for details. Representative images from three assays were shown. (C) Immunohistochemical staining with the pT120 antibody on
normal prostate tissue (left), in the presence of 20 nM antigenic phospho-peptide (middle) or 20 nM nonphospho-peptide (right).
doi:10.1371/journal.pone.0033830.g004
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C4-2 induces expression of E-cadherin and lowers tumor
incidence in mice xenograft models [24]. b-catenin serves as a
co-repressor of expression of prostate cancer metastasis repressor
gene KAI1 (CD82) [33]. We have previously shown that expression
of KAI1 actually was induced in C4-2/PKD1 cells, although the
expression of b-catenin is also upregulated [24]. These data
suggest that b-catenin protein levels do not necessarily correlate
with its transcription activity. In this study, we found that the
protein level of nuclear b-catenin in C-42/PKD1 is more
compared to C4-2 cells (Fig. 3B), but b-catenin transcription is
lower in C4-2/PKD1 cells (Fig. 1B). This finding cannot be merely
explained by induction of E-cadherin expression, because E-
cadherin is thought to sequester cytoplasm b-catenin pool and
decrease availability of free b-catenin for transcription in nucleus.
The pT120 antibody unveils the biochemical identity of nuclear b-
catenin in C4-2/PKD1 is T120 phosphorylated (also S37/T41
phosphorylated). In contrast, nuclear b-catenin in C4-2 is S37/
T41/T120 unphosphorylated. These findings suggest a possible
correlation among phosphorylation of these sites and crosstalk
between PKD1 and GSK3 signaling. A novel b-catenin pool in
TGN is also unveiled and is consistent with our previous finding
that PKD1 and b-catenin co-localized at TGN by using five TGN
and transport vehicle markers [28].
Although the critical role of Wnt signaling is demonstrated in
the mutations of APC or b-catenin gene, such mutations are
infrequent in prostate cancer, which counts 16% and 5%,
respectively [34]. Mutations of Axin1 in prostate cancer are also
reported [35]. In contrast, many studies have examined the
alterations in b-catenin expression and localization as a potential
new prostate cancer biomarker and the results vary from study to
study (see Table I in Ref. [35]). b-catenin immunostaining using a
conventional b-catenin antibody reveals that about 20–71% in
prostate cancer specimen have abnormal expression patterns of b-
catenin [36,37]. We observed 32.1% (18/56) samples have
increased b-catenin expression using H102 antibody (Table 2).
In contrast, we observe that 93% prostate cancer samples have
decreased pT120 b-catenin accumulation in TGN in both low and
high Gleason grade (Table 1). If this pT120 staining pattern truly
reflects PKD1 activity in vivo, then the results would be interpreted
that 93% prostate cancer samples have less PKD1 activity.
Interestingly, reduced expression of PKD1 was found in more than
95% of human invasive breast tumors examined by antibody
Figure 5. pT120 b-catenin is significantly decreased in TGN of prostate cancer samples. Immunohistological staining was performed with
H102 (panel A) and pT120 (panel B) antibodies on serial section of tissues. 3 and 4 are higher magnification of 1 and 2, respectively. 1 and 3 are
normal prostate tissue. 5 and 6 show that pT120 b-catenin predominantly distributes to plasma membrane and nucleus in tumor samples. Bars in
panels 1 and 2 equal to 50 micrometer. (C) Scatter plot for pT120 staining pattern in normal and prostate cancer samples. Normal and tumor samples
were counted for the ‘‘particle’’ staining pattern as described in Fig. 4B and 5B3. The number on Y-axis represents the average of two independent
counts. A cutoff at 30 (dashline) is used to as arbitrary definition of positive and negative staining.
doi:10.1371/journal.pone.0033830.g005
Table 1. Analysis of pT120 antibody staining in prostate cancer.
TransGolgi network staining Two-sample t test (P value)
n positive (%) negative (%) Normal vs. tumor Gleason 3–6 vs. 7–10
Normal 30 22 (73.3%) 8 (26.7%)
Tumor 197 14 (7.1%) 183 (92.9%) P,0.001
Gleason
3 to 6 27 4 (14.8%) 23 (85.2%)
7 to 10 170 10 (5.9%) 160 (94.1%) P,0.05
doi:10.1371/journal.pone.0033830.t001
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staining [19]. In 59% gastric cancer samples examined, PKD1 has
a .2-fold decrease in expression due to epigenetic silencing.
Our work reveals a new regulatory step of the dynamic
equilibrium of free and bound b-catenin. The phosphorylation of
T120 correlated inversely with unphosphorylated S37/T41 ABC.
The distribution of pT120 b-catenin is distinct in normal and
malignant prostate tissues. With malignant transformation,
staining of pT120 at TGN is dramatically decreased. We propose
that b-catenin T120 phosphospecific antibody can be used to
study alteration in subcellular distribution of b-catenin and Wnt
signaling, and possibly as biomarker in prostate and other tissues,
which may facilitate risk stratification or predict disease outcomes.
Further investigations on the phosphorylation relationship of T120
and S37/T41 may help to elucidate the role PKD1 in the
regulation of Wnt/b-catenin signaling.
Materials and Methods
Development of the pT120 antibody
An antigen peptide correspondent to the b-catenin T120 region,
109-IPSTQFDAAHPpTNVQRLAEPSQML (where pT is phos-
phothreonine-120) was synthesized. The peptide was injected into
two rabbits to raise antisera. A corresponding nonphospho-peptide
was also synthesized for antibody screening and purification. The
peptide synthesis and antibody generation was performed by
commercial contractor Millipore (Billerica, MA).
Western blotting and protein sample preparation
To prepare whole cell lysates, cells cultured on monolayer were
washed by phosphoate buffered saline (PBS) and dissolved in
RIPA buffer [25] (50 mM Tris-HCl, pH7.4, 150 mM NaCl, 0.5%
sodium deoxycholate, 0.1% SDS and 1% NP-40) plus protease
inhibitor cocktail (Sigma Chemicals, cat# P-8340). For fraction-
ation experiments, a commercial cell fractionation kit (the ProFEK
kit from ITSI Biosciences) was used according to manufacturer’s
recommendation. Briefly, cultured cells (56106) were collected by
scratching and washed with PBS plus a protease inhibitor cocktail
and a phosphatase inhibitor cocktail (A.G. Scientific, cat #P-
1517). Cell pellet was resuspended in 250 microliter of a hypotonic
buffer (Cytosol Buffer 1) and homogenized with a plastic pestle.
After incubation 15 min on ice, cells were centrifuged at 8,0006g
for 5 min. The supernatant was collected and centrifuged again at
16,0006g for 10 min and supernatant is used as soluble cytosol
fraction. The initial pellet was washed with a wash buffer (Wash
Buffer 2), spinned down, resuspended in 125 microliter of Nuclear
Buffer 3 and homogenized. After incubating on ice for 30 min, the
lysate was centrifuged at 16,0006g for 10 min. The supernatant
was collected as nuclear-protein enriched fraction. The resulting
pellet was resuspended in 250 microliter of Total Membrane
Buffer, homogenized and incubated on ice for 30 min. The lysate
was centrifuged at 16,0006g for 10 min and the supernatant was
collected as membrane-protein enriched fraction. It is worth
noting that the total membrane fraction generated by the kit
includes plasma membrane and cellular membrane. The protein
samples were separated on 10% SDS-PAGE and transferred to a
polyvinylidene difluoride membranes (PVDF) using a semi-dry
transfer devise (Thermo Scientific) at constant current model
(0.2 A). The membrane was then incubated with TBST (50 mM
Tris-HCl, pH7.4, 100 mM NaCl and 0.2% Tween-20) plus 3%
nonfat dry milk to block non-specific binding for 1 hour at room
temperature. Incubation with primary antibodies (see Reagents
section) was performed at 4 C for overnight. The densitometric
quantification of immunoblotting was carried out with Image J
software.
Reagents
For western blotting, the pT120 antiserum was used at dilution
of 1:2000. For peptide competition assay, the phospho- or
nonphospho-peptides were added in the pT120 antibody solution
to a final concentration of 20 nM prior to blotting. A commercial
b-catenin antibody (H102, Santa Cruz Biotechnology) was used
for comparison at 1:2000 dilution. The phospho-S33/S37/T41 b-
catenin antibody (Cell Signaling,) was used at dilution of 1:200 for
western blot. Monoclonal antibody 8E7 (Millipore) that recognizes
unphosphorylated S37/T41 b-catenin was used at 1:800 for
blotting. The HA-tagged wild type b-catenin in pCS2+ mamma-
lian expression vector, T120I and T102I/T112R/T120I mutants
were described previously [21]. The shRNA constructs targeting
PKD1 were purchased from Open Biosystems/Thermo Scientific
(Waltham, MA). Human recombinant Wnt-3a was purchased
from R&D Systems and used at 50 ng/ml in cell culture [26].
Cell cultures, treatment and Topflash assay
Prostate cancer cell lines LNCaP (clone FGC, from ATCC) C4-
2 (Urocor) and a benign prostate hyperplastic epithelial cell line
BPH-1 (kindly provided by Dr. Lucia Languino, Thomas Jefferson
University) were cultured in RPMI1640 medium plus 10% bovine
fetal serum (Invitrogen). C4-2 cells that stably express PKD1-GFP
(C4-2/PKD1) was previously described [27]. Normal prostate
epithelial cell line RWPE-1 (ATCC) was maintained in Keratino-
cyte Serum Free Medium (K-SFM, Invitrogen) and supplied with
bovine pituitary extract (Invitrogen) and human recombinant
epidermal growth factor (EGF, 5 ng/ml. Invitrogen). Mouse NIH
3T3 cell line was cultured in DMEM medium with 10% FBS.
Transient transfection was performed by Lipofectamine 2000
reagent (Invitrogen) overnight. Topflash assay conditions were
described previously [21]. Briefly, LNCaP cells (26104 cell/well in
a 96-well plate) were transfected by 50 ng Topflash reporter, 5 ng
Renilla luciferase vector and 100 ng either PKD1 expression
vector or empty vector control for overnight. Luciferase activity
was measured 2 days later. Relative luciferase activity (RLU) was
obtained by averaging of normalized firefly luciferase activities
from three samples. Normalization was performed with Renilla
luciferase from Promega (Madison, WI).
Immunofluorescence and immunohistochemistry
For immunofluorescence, cultured cells were fixed in 5%
formalin in PBS for 10 minutes at room temperature. Human
normal prostate tissues were deparafinized and rehydrated. The
pT120 and H102 antibodies were diluted 2000-fold in PBS with
0.1% Triton X-100 and 10 mg/ml BSA. Antibody to transGolgi
Table 2. Comparison of H102 and pT120 staining patterns.
Total H102 staining pT120 staining
Normal tissue
membranous bb-catenin 9 8 (88.9%)
TGN b-catenin 9 8 (88.9%)
Tumor tissue
increased expression 56 18 (32.1%) 9 (16.1%)
decreased expression 56 5 (8.9%) 5 (8.9%)
membranous 54 42 (77.8%) 8 (14.3%)
cytoplasm/nuclear 54 12 (22.2%) 6 (10.7%)
doi:10.1371/journal.pone.0033830.t002
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Network marker P230 (BD Transduction Laboratories) was used
at a dilution of 1:500. FITC and Cy3 labeled second antibodies
(Jackson ImmunoResearch, West Grove, PA) were used at dilution
of 1:1,000. For immunohistochemistry, the pT120 and H102
antibodies were used at 1:1000 and 1:100 dilutions, respectively.
Human prostate tissue arrays were purchased from US Biomax.
Fluorescence and IHC images were taken in an Olympus IX-51
microscope and a Nickon Eclipse 50i microscope equipped with
SPOT software, respectively. The assessment of b-catenin
expression in tissue specimens was done by comparison of the
average staining intensity of normal samples to the staining
intensities of tumor samples, and described higher or lower
intensity as up regulation or down regulation respectively. To
score pT120 staining in trans Golgi Network, we counted 30
normal prostate tissues for the ‘‘particle’’ staining pattern as
described in Figure 4 and Figure 5B3 by two reviewers
independently and average number of stained particles in the
whole core of each tissue was counted. Tumor tissues were defined
as positive or negative by an arbitrary cutoff of 30 particles per
core.
Semi-quantitative RT-PCR
Total RNA was extracted with Trizol reagent (Invitrogen).
Forty micrograms total RNA were used for reverse transcription in
a 40 ml volume using SuperScript II kit ((Invitrogen) at 45 C for
1 hour. After RT, the reaction was diluted with TE buffer (Tris-
HCl, 10 mM, pH8.0, EDTA 1 mM) to 200 microliter. Two
microliter of the RT product was used for each PCR reaction.
Thermocycle setting is 94 C for 2 minutes, 94 C for 30 seconds,
55 C for 45 seconds and 72 C for 30 seconds. PCR samples were
taken at 27, 29, 31 and 33 cycles and analyzed by agarose gel
electrophoresis. Wnt target genes were selected from a list in the
Wnt Homepage at http://www.stanford.edu/%7ernusse/
pathways/targets.html. Primers used are, c-Myc, For: ACCAG-
CTGGAGATGGTGACCGAG; Rev: CCGAGGACGGAGA-
GAAGGCGCT
cyclin D1, For: TGCTGAAGGCGGAGGAGACCTGC; Rev:
CAGCAGCTCCTCGGGCCGGATGG
Axin2, For: TTATGCTTTGCACTACGTCCCTCCA; Rev:
CGCAACATGGTCAACCCTCAGAC
LEF1, For: TTCAAGGACGAGGGCGATCCTCAAG; Rev:
CGAGTTATTCGGGTACATAATGA
ID2, For: AACAGCCTGTCGGACCACAAGC; Rev: GGC-
TGACAATAGTGGGATGCG
TCF1, For: TGGACAAGGGGGAGTCCTGC; Rev: GGT-
TGAGGCCAGTGGTATCG
GAPDH, For:AGAAGGCTGGGGCTCATTTG; Rev: AGG-
GGCCATCCACAGTCCTTC
Supporting Information
Figure S1 Total and pT120 b-catenin localizations in
cultured prostate cell lines. (a) C4-2 cells, (b) RWPE1 cells, (c)
LNCaP cells and (d) BPH-1 cells.
(TIF)
Figure S2 pT120 b-catenin staining in prostate tumor
and adjacent normal area. A tissue core contains both tumor
and normal tissues. The pT120 antibody staining reveals that
pT120 b-catenin accumulates in TGN in the normal tissues
(arrows, lower left). In adjacent tumor tissue, the pT120 b-catenin
is more diffused in cytoplasm (upper left).
(TIF)
Acknowledgments
We thank the University Massachusetts Medical School DERC core
facility for IHC work.
Author Contributions
Conceived and designed the experiments: CD KCB. Performed the
experiments: CD CZ ZL HUB. Analyzed the data: CD CZ ZL HUB
KCB. Contributed reagents/materials/analysis tools: CD ZL CZ. Wrote
the paper: CD KCB.
References
1. Nelson WJ, Nusse R (2004) Convergence of Wnt, beta-catenin, and cadherin
pathways. Science 303: 1483–1487.
2. van Roy F, Berx G (2008) The cell-cell adhesion molecule E-cadherin. Cell Mol
Life Sci 65: 3756–3788.
3. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, et al. (2002) Linking beta-
catenin to androgen-signaling pathway. J Biol Chem 277: 11336–11344.
4. Chesire DR, Isaacs WB (2002) Ligand-dependent inhibition of beta-catenin/
TCF signaling by androgen receptor. Oncogene 21: 8453–8469.
5. Graham TA, Weaver C, Mao F, Kimelman D, Xu W (2000) Crystal structure of
a beta-catenin/Tcf complex. Cell 103: 885–896.
6. Pokutta S, Weis WI (2000) Structure of the dimerization and beta-catenin-
binding region of alpha-catenin. Mol Cell 5: 533–543.
7. Daugherty RL, Gottardi CJ (2007) Phospho-regulation of Beta-catenin adhesion
and signaling functions. Physiology (Bethesda) 22: 303–309.
8. Maher MT, Mo R, Flozak AS, Peled ON, Gottardi CJ Beta-catenin
phosphorylated at serine 45 is spatially uncoupled from beta-catenin phosphor-
ylated in the GSK3 domain: implications for signaling. PLoS One 5: e10184.
9. Maher MT, Flozak AS, Stocker AM, Chenn A, Gottardi CJ (2009) Activity of
the beta-catenin phosphodestruction complex at cell-cell contacts is enhanced by
cadherin-based adhesion. J Cell Biol 186: 219–228.
10. Faux MC, Coates JL, Kershaw NJ, Layton MJ, Burgess AW () Independent
interactions of phosphorylated beta-catenin with E-cadherin at cell-cell contacts
and APC at cell protrusions. PLoS One 5: e14127.
11. van Noort M, Meeldijk J, van der Zee R, Destree O, Clevers H (2002) Wnt
signaling controls the phosphorylation status of beta-catenin. J Biol Chem 277:
17901–17905.
12. van Noort M, Weerkamp F, Clevers HC, Staal FJ (2007) Wnt signaling and
phosphorylation status of beta-catenin: importance of the correct antibody tools.
Blood 110: 2778–2779.
13. Hendriksen J, Jansen M, Brown CM, van der Velde H, van Ham M, et al.
(2008) Plasma membrane recruitment of dephosphorylated beta-catenin upon
activation of the Wnt pathway. J Cell Sci 121: 1793–1802.
14. Maher MT, Mo R, Flozak AS, Peled ON, Gottardi CJ (2010) Beta-catenin
phosphorylated at serine 45 is spatially uncoupled from beta-catenin
phosphorylated in the GSK3 domain: implications for signaling. PLoS One 5:
e10184.
15. Wang QJ (2006) PKD at the crossroads of DAG and PKC signaling. Trends
Pharmacol Sci 27: 317–323.
16. Jaggi M, Du C, Zhang W, Balaji KC (2007) Protein kinase D1: a protein of
emerging translational interest. Front Biosci 12: 3757–3767.
17. Jaggi M, Rao PS, Smith DJ, Hemstreet GP, Balaji KC (2003) Protein kinase C
mu is down-regulated in androgen-independent prostate cancer. Biochem
Biophys Res Commun 307: 254–260.
18. Kim M, Jang HR, Kim JH, Noh SM, Song KS, et al. (2008) Epigenetic
inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer
cell migration and invasion. Carcinogenesis 29: 629–637.
19. Eiseler T, Doppler H, Yan IK, Goodison S, Storz P (2009) Protein kinase D1
regulates matrix metalloproteinase expression and inhibits breast cancer cell
invasion. Breast Cancer Res 11: R13.
20. Fielitz J, Kim MS, Shelton JM, Qi X, Hill JA, et al. (2008) Requirement of
protein kinase D1 for pathological cardiac remodeling. Proc Natl Acad Sci U S A
105: 3059–3063.
21. Du C, Jaggi M, Zhang C, Balaji KC (2009) Protein Kinase D1-
Mediated Phosphorylation and Subcellular Localization of {beta}-Catenin.
Cancer Res.
22. Aberle H, Schwartz H, Hoschuetzky H, Kemler R (1996) Single amino acid
substitutions in proteins of the armadillo gene family abolish their binding to
alpha-catenin. J Biol Chem 271: 1520–1526.
23. Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, et al. (2005) Aberrant
expression of E-cadherin and Beta Catenin in Human Prostate Cancer. Urologic
Oncology: Seminars and Original Investigations 23: 402–406.
24. Du C, Zhang C, Hassan S, Biswas MH, Balaji KC (2010) Protein kinase D1
suppresses epithelial-to-mesenchymal transition through phosphorylation of
snail. Cancer Res 70: 7810–7819.
Beta-Catenin T120 Phosphorylation
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e33830
25. Alcaraz C, De Diego M, Pastor MJ, Escribano JM (1990) Comparison of a
radioimmunoprecipitation assay to immunoblotting and ELISA for detection of
antibody to African swine fever virus. J Vet Diagn Invest 2: 191–196.
26. Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, et al. (2008) Prostate
cancer induces bone metastasis through Wnt-induced bone morphogenetic
protein-dependent and independent mechanisms. Cancer Res 68: 5785–5794.
27. Jaggi M, Rao PS, Smith DJ, Wheelock MJ, Johnson KR, et al. (2005) E-
cadherin phosphorylation by protein kinase D1/protein kinase C{mu} is
associated with altered cellular aggregation and motility in prostate cancer.
Cancer Res 65: 483–492.
28. Jaggi M, Chauhan SC, Du C, Balaji KC (2008) Bryostatin 1 modulates beta-
catenin subcellular localization and transcription activity through protein kinase
D1 activation. Mol Cancer Ther 7: 2703–2712.
29. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, et al. (1994)
Androgen-independent cancer progression and bone metastasis in the LNCaP
model of human prostate cancer. Cancer Res 54: 2577–2581.
30. Sharlow ER, Giridhar KV, LaValle CR, Chen J, Leimgruber S, et al. (2008)
Potent and selective disruption of protein kinase D functionality by a
benzoxoloazepinolone. J Biol Chem 283: 33516–33526.
31. Bek S, Kemler R (2002) Protein kinase CKII regulates the interaction of beta-
catenin with alpha-catenin and its protein stability. J Cell Sci 115: 4743–4753.
32. Zugaza JL, Sinnett-Smith J, Van Lint J, Rozengurt E (1996) Protein kinase D
(PKD) activation in intact cells through a protein kinase C-dependent signal
transduction pathway. Embo J 15: 6220–6230.
33. Kim JH, Kim B, Cai L, Choi HJ, Ohgi KA, et al. (2005) Transcriptional
regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes.
Nature 434: 921–926.
34. Chesire DR, Isaacs WB (2003) Beta-catenin signaling in prostate cancer: an
early perspective. Endocr Relat Cancer 10: 537–560.
35. Whitaker HC, Girling J, Warren AY, Leung H, Mills IG, et al. (2008)
Alterations in beta-catenin expression and localization in prostate cancer.
Prostate 68: 1196–1205.
36. Verras M, Sun Z (2006) Roles and regulation of Wnt signaling and beta-catenin
in prostate cancer. Cancer Lett 237: 22–32.
37. Yardy GW, Bicknell DC, Wilding JL, Bartlett S, Liu Y, et al. (2009) Mutations in
the AXIN1 gene in advanced prostate cancer. Eur Urol 56: 486–494.
Beta-Catenin T120 Phosphorylation
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e33830
